In this multicenter ambispective cohort of 3305 Chinese patients with type 2 diabetes, renal impairment, and elevated cardiovascular risk, polyethylene glycol-loxenatide was associated with a reduced risk of major renal events, whereas the cardiovascular (3-point MACE) association was not sustained after propensity score matching and is considered exploratory.
Polyethylene glycol-loxenatide was associated with a lower risk of the primary kidney composite outcome in the original (unmatched) cohort.
The renal association was corroborated in the 1:1 propensity score matched cohort.
Landmark analyses addressing immortal time bias showed progressively stronger renal associations with longer treatment exposure.
A reduction in 3-point major adverse cardiovascular events (MACE) in the unmatched cohort was not sustained after propensity score matching.
The study used an ambispective multicenter design with AI-enhanced data extraction and two co-primary analytic approaches.
The authors conclude that long-term therapy was associated with an attenuated risk of major renal events in high-risk Chinese patients.
This study looked at whether a once-weekly diabetes drug called polyethylene glycol-loxenatide, which works like the GLP-1 hormone, was linked to better kidney outcomes in people with type 2 diabetes who already had kidney problems and higher heart risk. Researchers reviewed records of 3305 patients at six Chinese hospitals, followed for a median of about 3 years, and compared those taking the drug with those on standard care that did not include incretin-based drugs. People taking the drug had about half the risk of serious kidney events (such as worsening kidney function) compared with those who did not. This finding held when patients were carefully matched on their characteristics (332 per group) and when the analysis was designed to avoid giving the drug credit for the early, event-free time before treatment began. The apparent benefit looked larger in people who had stayed on the drug for longer. The heart-related findings were less clear. Heart events looked lower with the drug in the full group, but this disappeared after matching, so the authors treat it as tentative. Because this was an observational study rather than a randomized trial, it cannot prove that the drug caused the kidney benefit. This research suggests the drug may be linked to kidney protection, and the authors say randomized trials are needed to confirm this.
Ye J, Li J, Chen Y, Chen F, Zhu D, Zhang C, et al.. (2026). Real-world renoprotective effects of polyethylene glycol-loxenatide in type 2 diabetes: a multicenter, ambispective cohort study.. Signal transduction and targeted therapy. https://doi.org/10.1038/s41392-026-02945-5